pharma · Head and Neck Squamous Cell Carcinoma · Metastatic Head and Neck Squamous Cell Carcinoma · BCAX
Bicara Therapeutics
Bicara Therapeutics is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker BCAX. Primary therapeutic focus areas include Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squa
Boston, USA HQ
2020 Founded
115 Employees
Public company Type
BCAX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boston, USA
- Founded
- 2020
- Employees
- 115
- Programs
- 6
- Drugs
- 4
- Patents
- 0
BCA101X301
Phase 3 · small molecule · Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
BCA101X301 for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. is a Phase 3 program (small_molecule) at Bicara Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code BCA101X301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Bicara Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
- Status
- active
- Trials
- 1